Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population

Conditions:   Chronic Myeloid Leukemia;   Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission;   Chronic Myeloid Leukemia in Remission Interventions:   Other: Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Withdrawal;   Drug: Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Re-initiation Sponsor:   Baylor College of Medicine Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials